Ductal adenocarcinoma of the pancreas (PDAC) accounts for more than 85% of PC and is an aggressive malignancy characterized by a high rate of distant metastasis and recurrence. Compared with other types of cancer, PC has a unique TEM that accounts for more than 80% of total pancreatic tumor masses, consisting of the extracellular matrix and numerous types of cellular components. Among them, cancer-associated fibroblasts (CAFs) are responsible for the production of extracellular matrix and regulation of tumor behavior, forming a physical barrier for drug delivery and leading to medication resistance.
Alfa Oncology is a leading custom service provider with experience in pancreatic cancer (PC) basic research. We are now proud to offer a full range of PC basic research services. Based on robust platforms, powerful analytics, cross-platform collaborations, and years of experience in the PC field, we are committed to providing our customers with optimal customized services to meet their needs of PC basic research.
Learn more：pathology research on PC
